Showing results (461-470 of 470) with videos related to
Sort By:
Pageof 47
You have reached the last page of results.This site can display upto 470 results.
Brain Pathology (Zurich, Switzerland)|November 18, 2014
Melanotic tumors of the nervous system are characterized by distinct mutational, chromosomal and epigenomic profilesChristian Koelsche, Volker Hovestadt, David T W Jones, et al.Magnetic Resonance in Medicine|December 8, 2022
Submillimeter T1 atlas for subject-specific abnormality detection at 7TGian Franco Piredda, Samuele Caneschi, Tom Hilbert, et al.The Lancet. Oncology|December 22, 2025
O-(2-[18F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trialAnca-Ligia Grosu, Wolfgang A Weber, Erika Graf, et al.Neuro-Oncology|November 10, 2017
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastomaNiklas Schäfer, Martin Proescholdt, Joachim P Steinbach, et al.Alzheimer'S Research & Therapy|May 3, 2022
Comparative analysis of machine learning algorithms for multi-syndrome classification of neurodegenerative syndromesLeonie Lampe, Sebastian Niehaus, Hans-Jürgen Huppertz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS TrialUlrich Herrlinger, Niklas Schäfer, Joachim P Steinbach, et al.Lancet (London, England)|February 21, 2019
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trialUlrich Herrlinger, Theophilos Tzaridis, Frederic Mack, et al.Nature Genetics|January 12, 2023
Comprehensive multi-omic profiling of somatic mutations in malformations of cortical developmentChanguk Chung, Xiaoxu Yang, Taejeong Bae, et al.Medical Image Analysis|August 1, 2016
ISLES 2015 - A public evaluation benchmark for ischemic stroke lesion segmentation from multispectral MRIOskar Maier, Bjoern H Menze, Janina von der Gablentz, et al.The New England Journal of Medicine|October 26, 2017
Histopathological Findings in Brain Tissue Obtained during Epilepsy SurgeryIngmar Blumcke, Roberto Spreafico, Gerrit Haaker, et al.Pageof 47